Zeracizumab is an investigational angiogenesis inhibitor that targets vascular endothelial growth factor and is being evaluated for the treatment of advanced non-squamous non-small cell lung cancer that has not responded to chemotherapy (NSCLC). To establish the clinical effectiveness of the experimental treatment, the pharma firm analyzes 1-year survival following treatment as part of the review procedure. The outcomes are shown in the table below. Which of the following best describes the zeracizumab-containing regimen's number needed to harm?

Question

Zeracizumab is an investigational angiogenesis inhibitor that targets vascular endothelial growth factor and is being evaluated for the treatment of advanced non-squamous non-small cell lung cancer that has not responded to chemotherapy (NSCLC). To establish the clinical effectiveness of the experimental treatment, the pharma firm analyzes 1-year survival following treatment as part of the review procedure. The outcomes are shown in the table below.   Which of the following best describes the zeracizumab-containing regimen's number needed to harm?

Quizplus · Accepted Answer

Eductional Objective: The number required to harm (NNH) is the number of persons who must be treated before one more negative event happens. The absolute risk increase between the treatment and control groups must be known in order to compute NNH: NNH = 1 / Increase in absolute risk

Zeracizumab Is an Investigational Angiogenesis Inhibitor That Targets Vascular Endothelial